Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418424 | 0.92 | HTR1A (0.48) | HTR1ASLC6A4CYP2D6MAOBGRM2 | |
| SCHEMBL6415311 | 0.91 | HTR1A (0.58) | HTR1ASLC6A4ACHE | |
| SCHEMBL6417847 | 0.89 | HTR1A (0.49) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL6411647 | 0.89 | HTR1A (0.49) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL6415288 | 0.88 | HTR1A (0.48) | HTR1ASLC6A4CYP2D6GRM2ACHE | |
| SCHEMBL6418007 | 0.88 | HTR1A (0.48) | HTR1ASLC6A4CYP2D6GRM2 | |
| SCHEMBL6416433 | 0.87 | HTR1A (0.52) | HTR1ASLC6A4CYP2D6MAOB | |
| SCHEMBL6418927 | 0.87 | HTR1A (0.64) | HTR1ASLC6A4 | |
| SCHEMBL6411252 | 0.84 | HTR1A (0.49) | HTR1ASLC6A4CYP2D6 | |
| SCHEMBL6412783 | 0.83 | HTR1A (0.52) | HTR1ASLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | HTR1A 1/4885SLC6A4 2/4885CYP2D6 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.